Viewing Expert Gordon Reid | StockChase
stockchase picture

Compiling comments that experts make about stocks while on public TV.

Viewing Expert

Gordon Reid , President

GoodReid Investment Counsel

Address
47 Colborne Street
Suite 400
Toronto, ON
M5E 1P8

Contact Info
Telephone: 416.364.0890
Toll Free: 1.888.466.3734
Fax: 416.364.1788
Email:


Date Signal Chart Symbol Company Opinion Price
2017-06-21 N/A Must be logged in to use chart A Commentary A Comment -- General Comments From an Expert

Market. The average investor tends to concentrate on the P of the P/E. They are really interested in price and believe that if the price goes up it is good, but if it goes down it is bad. That is not the way real life works. People tend to judge the company, but are not equipped to analyse the depths that the professionals do. They spend too much time looking at macro issues, trying to figure out whether politics or policy is going to have a bad effect on their holdings. Politicians come and go. Companies and stock prices are driven by the abilities of companies and management to drive earnings, revenues and cash flow.


Price:
$0.020
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
_N/A
2017-06-21 HOLD Must be logged in to use chart AAPL-Q Apple

People have been saying that the Apple phone is going to fail for as long as he can remember. This has done very, very well for his clients. He has trimmed his holdings 8 times. A 3rd of their market capitalization is in cash. The iPhone 8 is the 10th anniversary of the iPhone. They are putting a lot of money behind R&D, and he thinks there are some good things that are going to come out. There is a 93% loyalty rate amongst Apple buyers.


Price:
$145.870
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
Yes
2017-06-21 DON'T BUY Must be logged in to use chart ABBV-N AbbVie Inc.

(Market Call Minute.) The spinoff from Abbott Labs (ABT-N). What makes him hesitate about this is that it is more of a 1 product company with their Humira drug. It represents about 65% of their total revenue, so that presents risks.


Price:
$71.340
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
Unknown
2017-06-21 COMMENT Must be logged in to use chart BAC-N Bank of America

Longer-term, this has more upside. It had a very sharp rise from early November. A lot of the banks have gone up on the Trump trade and then back down. This hasn’t come right back down, because it is more of a valuation play than the pure growth play. Wait for the yield curve to steepen.


Price:
$23.130
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
Yes
2017-06-21 PAST TOP PICK Must be logged in to use chart C-N CitiGroup

(A Top Pick June 15/16. Up 54%.) He knew that sooner or later the Fed was going to do an about-face and start to tighten, which would help the banks.


Price:
$63.830
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
Yes
2017-06-21 TOP PICK Must be logged in to use chart CVS-N CVS Health Corp

One reason he likes this is that it is out of favour. We always have to gravitate to things that will do well in the future as opposed to what has done well in the past. This is a combination of CVS the drugstore and Caremark, a pharmacy benefits manager. They sell over 1 billion prescriptions a year and have over 10,000 locations in the US. As it stays out of favour, it gets more and more compelling from a valuation standpoint. Based on next year’s expectations of earnings, it is trading at a little over 12X earnings, well below the market multiple. Dividend yield of 2.5%. (Analysts’ price target is $88.)


Price:
$78.160
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
Yes
2017-06-21 SELL Must be logged in to use chart DIS-N Walt Disney

This has been a tough Hold for people. It has gone sideways for about 2.5 years. Their major franchise is their TV network of ABC and ESPN. The fear is that there is going to be severe cord cutting and the “skinny bundle” is going to appear. This has led to the multiple falling because people don’t have as much confidence in the long-term prospects of the earnings growth. Their other franchises are doing extremely well. Currently it is trading at about 15.5-16 times earnings, below the market multiple. He would suggest you move on. There are lots of fish in the sea.


Price:
$104.800
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
Unknown
2017-06-21 TOP PICK Must be logged in to use chart DOOR-N Masonite International Corp

Makes exterior and interior residential and commercial doors. They are in 65 countries around the world. If you are a believer in the increasing home ownership globally, and in the US in particular, and household formations improving and increasing, this company should do well. Their margins are improving, which is always a good thing. (Analysts’ price target is $85.)


Price:
$73.200
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
Yes
2017-06-21 COMMENT Must be logged in to use chart GE-N General Electric

Often what happens when a new regime comes in, they tend to throw the kitchen sink in with the next earnings report, and get rid of anything that is bad. He suspects that will happen. Their estimates of cash flow and earnings were high, and were not going to be able to achieve them. Longer-term, this is constructive.


Price:
$27.780
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
Unknown
2017-06-21 COMMENT Must be logged in to use chart GILD-Q Gilead Sciences Inc.

(Market Call Minute.) Pretty much a one product company treating hepatitis C. Sales are falling and the price is being challenged. The good news is that they have a huge cache of cash, 30%.


Price:
$67.500
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
No
2017-06-21 BUY Must be logged in to use chart GOOGL-Q Alphabet Inc. (A)

(Market Call Minute.) A fantastic franchise. They continue to grow revenue using cash flow into the 20% range. They are monetizing areas that they weren’t years ago.


Price:
$978.590
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
Yes
2017-06-21 DON'T BUY Must be logged in to use chart JPM-N JP Morgan Chase & Co

(Market Call Minute.) This has done a very good job. They came through 2008 as one of the best of the banks. A higher multiple bank, trading at 1.4X BV. He would probably go with some of the other banks instead.


Price:
$87.120
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
Unknown
2017-06-21 DON'T BUY Must be logged in to use chart MRK-N Merck & Company

Pfizer (PFE-N) or Merck (MRK-N)? Neither. These companies did very, very well back in the last part of the last century. Patent protection laws really haven’t given them enough of a boost to be able to cover the enormous costs of developing and testing the drugs, and there is a high failure rate. The companies have made massive consolidations. They’ve tried to grow by spending less. He would look at the Bio-Pharma area instead, such as Biogen (BIIB-Q) or Celgene (CELG-Q). Financially, these companies are in good shape and are growing.


Price:
$65.460
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
Unknown
2017-06-21 COMMENT Must be logged in to use chart MSFT-Q Microsoft

This company went through a very, very strong growth period. It has run up the valuation ladder and then has come down. The fundamentals of revenue growth, cash flow growth and earnings growth have been steady and uninspiring over time. People now have faith in the new CEO and the Cloud, so it is going up the valuation ladder again. This is an OK buy here. A little bit expensive. He thinks there are lots of other technology companies to look at.


Price:
$70.270
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
No
2017-06-21 DON'T BUY Must be logged in to use chart NKE-N Nike Inc

(Market Call Minute.) He would pass on this. It is being challenged by Under Armour (UA-N) and Adidas (ADS-GR). It trades at a fairly healthy multiple.


Price:
$52.590
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
Unknown
Showing 1 to 15 of 1,996 entries
<< < 1 2 3 4 5 > >>

No Comments.


You must be logged in to comment.